Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma.
Eur J Cancer
; 27(12): 1637-9, 1991.
Article
em En
| MEDLINE
| ID: mdl-1782075
Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Sarcoma de Kaposi
/
Teniposídeo
/
Síndrome da Imunodeficiência Adquirida
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
Limite:
Adult
/
Humans
/
Male
Idioma:
En
Revista:
Eur J Cancer
Ano de publicação:
1991
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Reino Unido